Reality Check on PCSK9
Market access for PCSK9s reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: More than 90% of the lives under the pharmacy benefit in commercial and health exchange formularies have utilization management restrictions on PCSK9 inhibitors
- Class Trends: In October 2018, Amgen said that it would reduce the price of its Repatha SureClick autoinjector to $5,850 per year
- Key Findings: Coverage is highly restricted with multiple steps and a laundry list of prior-authorization restrictions
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.